NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
April 05, 2024 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today reported that it received a notice (the “Notice) on April 4, 2024 from the...
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
September 08, 2023 07:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the...
NeuBase Therapeutics to Explore Strategic Alternatives
August 03, 2023 07:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene...
NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
June 30, 2023 16:05 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene...
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing
June 29, 2023 08:30 ET
|
NeuBase Therapeutics, Inc.
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to...
NeuBase Announces $5 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
June 28, 2023 14:17 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene...
NeuBase Announces 1-for-20 Reverse Stock Split
June 14, 2023 08:30 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, June 14, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene...
NeuBase to Participate in Jefferies Healthcare Conference
May 24, 2023 08:00 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, May 24, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene...
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™
May 22, 2023 07:00 ET
|
NeuBase Therapeutics, Inc.
Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machineryData show that Stealth Editors™ do not elicit a...
NeuBase Announces Formation of Gene Editing Advisory Board
May 16, 2023 16:01 ET
|
NeuBase Therapeutics, Inc.
PITTSBURGH, May 16, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene...